In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
The Anthropic co-founder Jack Clark tells Ezra Klein what he sees coming in the new era of A.I. agents. This is an edited transcript of “The Ezra Klein Show.” You can listen to the episode wherever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results